Hologic Outruns Estimates Again

Hologic (NAS: HOLX) reported earnings on Jan. 30. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 24 (Q1), Hologic beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew, and GAAP earnings per share grew significantly.

Gross margins expanded, operating margins were steady, net margins increased.

Revenue details
Hologic logged revenue of $472.7 million. The 21 analysts polled by S&P Capital IQ predicted sales of $466.4 million. Sales were 9.3% higher than the prior-year quarter's $432.6 million.


Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
Non-GAAP EPS came in at $0.34. The 24 earnings estimates compiled by S&P Capital IQ averaged $0.32 per share on the same basis. GAAP EPS of $0.8 for Q1 were 100% higher than the prior-year quarter's $0.04 per share.


Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 62.5%, 50 basis points better than the prior-year quarter. Operating margin was 17.4%, about the same as the prior-year quarter. Net margin was 4.4%, 190 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $470.8 million. On the bottom line, the average EPS estimate is $0.33.

Next year's average estimate for revenue is $1.91 billion. The average EPS estimate is $1.36.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 697 members out of 717 rating the stock outperform, and 20 members rating it underperform. Among 213 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 208 give Hologic a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $21.45.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Hologic the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.

At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story